Wat is de prijs voor Mega Genomics Limited (6667)

Het prijs van Mega Genomics Limited (6667) is $0.90827623

Wat is de marktkapitalisatie voor Mega Genomics Limited (6667)

Marktkapitalisatie voorMega Genomics Limited (6667) is $203.73M

Mega Genomics Limited (6667) Prijs en Marktkapitalisatie

Mega Genomics Limited, a genetic testing platform company, offers consumer genetic testing and cancer screening services in China. It offers brain health assessment package, a service that assesses the risk of various related diseases, including Alzheimer’s disease; alimentation capability assessment package, a service that assesses the risk of developing hyperhomocysteinemia; Parkinson’s disease risk assessment; full-scale cancer risk assessment packages; myocardial infarction and heart failure genetic testing, a service and ancillary service that assesses the genetic risk of developing myocardial infarction and heart failure; cardiovascular and cerebrovascular disease risk assessment packages; hereditary breast cancer/ovarian cancer genetic testing; Septin9 colorectal cancer screening test; RNF180/Septin9 gastric cancer screening test; cervical cancer genetic methylation testing, a cervical cancer test; telomere length genetic testing that assesses the cell age and aging rate of a person; and personal whole genome test plus, a service that assesses the risk of developing multiple types of diseases and provides interpretation for various individual traits and medication advice. It also offers whole exome sequencing package for adults, a service that assesses the risk of developing multiple high-risk diseases, hereditary cancers, recessive genetic diseases, and types of complex diseases, as well as multiple drugs, dietary nutrition items, and exercise and fitness items; folate metabolic capacity assessment testing kits to assess the risk of developing cardiovascular and cerebrovascular diseases; ApoE gene testing for testing Alzheimer’s disease; BRCA1/2 gene mutation testing kits; Alzheimer’s disease screening kits; colorectal cancer screening kits; gastric cancer screening kits; lung nodule auxiliary diagnostic kits; and cervical cancer screening kits to health checkup centers and hospitals. The company was founded in 2016 and is headquartered in Beijing, China.

Prijs voor 6667	Aandeel B	Marktkapitalisatie van B	uitslagen
$24,183.18 $203.73M	NVDA	$5.424T	+2,662,436.23%
$21,292.39 $203.73M	AAPL	$4.776T	+2,344,163.80%
$18,064.24 $203.73M	GOOG	$4.052T	+1,988,749.24%
$16,455.80 $203.73M	MSFT	$3.691T	+1,811,661.45%
$12,234.69 $203.73M	AMZN	$2.744T	+1,346,923.21%

Prijs voor 6667

Aandeel B

Marktkapitalisatie van B

uitslagen

$24,183.18 $203.73M